Courtesy of Benzinga.
Analysts at UBS downgraded Impax Laboratories Inc (NASDAQ: IPXL) from Neutral to Sell.
Impax Laboratories shares have gained 99.84 percent over the past 52 weeks, while the S&P 500 index has gained 12.45 percent in the same period.
Impax Laboratories’ shares declined 3.04 percent to $49.70 in pre-market trading.
Latest Ratings for IPXL
Date | Firm | Action | From | To |
---|---|---|---|---|
Apr 2015 | UBS | Downgrades | Neutral | Sell |
Apr 2015 | Deutsche Bank | Initiates Coverage on | Hold | |
Apr 2015 | Leerink Swann | Maintains | Market Perform |
View More Analyst Ratings for IPXL
View the Latest Analyst Ratings
Posted-In: UBSDowngrades Analyst Ratings